MedTrace Logo

PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer

NCT03006614 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2017-01-16

No results posted yet for this study

Summary

This study aims to explore new PERS prediction model can improve the pathological complete response rate of neoadjuvant chemotherapy of breast cancer and disease-free survival.

Conditions

Interventions

DRUG

NVB

DRUG

EPI

DRUG

DDP

DRUG

CAP

DRUG

GEM

DRUG

H

DRUG

CTX

DRUG

T

Sponsors & Collaborators

  • Shi Yanxia

    lead OTHER

Principal Investigators

  • YanXia Shi, doctor · Sun Yat-sen university of cancer center Recruiting

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2018-03-31
Completion
2023-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03006614 on ClinicalTrials.gov